Objective: To retrospectively evaluate the utility of serum and cerebrospinal fluid (CSF)
levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain …

Objective: To determine the safety and tolerability of nusinersen treatment in ambulatory
adults with spinal muscular atrophy (SMA) and investigate the treatment effect on muscle …

Objective Spinal muscular atrophy (SMA) is a motor neuron disease caused by low levels of
survival motor neuron (SMN) protein. Prior work in models and patients has demonstrated …

Abstract Background and Objectives Multiple variables play a role in spinal cord stimulation
(SCS) treatment outcomes, including patient anatomy, pain pattern, lead location …

Objective: Investigation of the safety, tolerability, and treatment effect of nusinersen treatment
in non-ambulatory adults with spinal muscular atrophy (SMA). Methods: Non-ambulatory …

IMPLICATIONS: We analyzed the members of several pain medicine boards by using
published directories and Internet databases. The American Board of Medical Specialties …

Objective: Investigate quality of life (QoL) in adults with genetically proven Spinal Muscular
Atrophy (SMA) at baseline and after 14 months of Nusinersen therapy. Background …

Objective: 1. To characterize factors influencing health-related quality of life (Qol). 2. To track
changes in Qol overtime after treatment with disease-modifying therapy in a cohort of adult …

The array of minimally invasive interventions for chronic head and neck pain has grown
rapidly with the advent of technologies that allow for targeting of various components of the …

Objective: The objectives of the current study were to: 1. Examine adult individuals (> 18
years of age) with spinal muscular atrophy (SMA) for evidence of neuromuscular junction …